文献速递肾小球疾病

纤维样肾小球肾炎诊断新进展:DNAJB9生物标志物

New developments in the diagnosis of fibrillary glomerulonephritis.
PubMed 文献 · Kidney Int · 2019-04-09

纤维样肾小球肾炎是一种以Congo红阴性、随机排列的直纤维沉积为特征肾小球疾病,预后差,近半数患者4年内进展至终末期肾病。近期通过激光显微切割辅助液相色谱-串联质谱鉴定出新型组织生物标志物DNAJB9,免疫组化证实其高敏感性和特异性,双免疫荧光显示与IgG共定位,免疫电镜显示定位于单个纤维。该标志物已进入临床实践,有望改善尤其电镜不可及地区的诊断。

要点

  • DNAJB9是纤维样肾小球肾炎的高敏感性、高特异性组织生物标志物。
  • DNAJB9与IgG在肾小球共定位,并定位于纤维样肾小球肾炎的单个纤维。
  • 该标志物已进入临床实践,有助于在电镜不可及地区改善诊断。

核心结论

  • DNAJB9作为新型组织生物标志物,已进入临床实践,将改善纤维样肾小球肾炎的诊断,尤其在电镜不可及的发展中国家。

研究设计与样本

  • 综述性文章,总结纤维样肾小球肾炎诊断的最新进展,未报告系统检索范围或样本量。

主要发现

  • 近半数纤维样肾小球肾炎患者在4年内进展至终末期肾病。
  • 肾移植后约三分之一病例出现疾病复发。
  • 通过激光显微切割辅助液相色谱-串联质谱鉴定出DNAJB9为纤维样肾小球肾炎的新型生物标志物。
  • 免疫组化证实DNAJB9对该疾病具有高敏感性和特异性。
  • 双免疫荧光显示DNAJB9与IgG在肾小球共定位,免疫电镜显示其定位于单个纤维。

临床怎么用

  • DNAJB9免疫组化可作为纤维样肾小球肾炎的诊断工具,尤其在电镜不可及的地区。
  • 该标志物已进入临床实践,有助于提高这一罕见疾病的诊断准确性。

局限性

  • DNAJB9是否为自身抗原或仅关联蛋白尚不明确。
  • DNAJB9能否作为无创生物标志物尚待研究。
  • 靶向DNAJB9的治疗是否有效改善预后尚需未来研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibrillary glomerulonephritis is a glomerular disease historically defined by glomerular deposition of Congo red-negative, randomly oriented straight fibrils that lack a hollow center and stain with antisera to immunoglobulins. It was initially considered to be an idiopathic disease, but recent studies highlighted association in some cases with autoimmune disease, malignant neoplasm, or hepatitis C viral infection. Prognosis is poor with nearly half of patients progressing to end-stage renal disease within 4 years. There is currently no effective therapy, aside from kidney transplantation, which is associated with disease recurrence in a third of cases. The diagnosis has been hampered by the lack of biomarkers for the disease and the necessity of electron microscopy for diagnosis, which is not widely available. Recently, through the use of laser microdissection-assisted liquid chromatography-tandem mass spectrometry, a novel biomarker of fibrillary glomerulonephritis, DnaJ homolog subfamily B member 9, has been identified. Immunohistochemical studies confirmed the high sensitivity and specificity of DnaJ homolog subfamily B member 9 for this disease; dual immunofluorescence showed its colocalization with IgG in glomeruli; and immunoelectron microscopy revealed its localization to individual fibrils of fibrillary glomerulonephritis. The identification of this tissue biomarker has already entered clinical practice and undoubtingly will improve the diagnosis of this rare disease, particularly in developing countries where electron microscopy is less available. Future research is needed to determine whether DnaJ homolog subfamily B member 9 is an autoantigen or just an associated protein in fibrillary glomerulonephritis, whether it can serve as a noninvasive biomarker, and whether therapies that target this protein are effective in improving prognosis.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Nasr SH, Fogo AB. New developments in the diagnosis of fibrillary glomerulonephritis. Kidney Int. 2019. PMID: 31227146. doi:10.1016/j.kint.2019.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。